Evotec Q1 Adj. EBITDA Down, Revenues Up

Evotec AG (EVTCY.PK), a German drug discovery and development company, on Wednesday posted lower adjusted EBITDA for the first quarter, driven by capacity expansions at all sites. However, revenues grew 24 percent in the quarter.

The Group's adjusted EBITDA slid to 18.9 million euros from 21.1 million euros, mainly driven by capacity expansions at all sites, in particular the continued ramp-up of J.POD Redmond (US) facility.

For the quarter, the Group revenues grew by 24 percent to 164.7 million euros from last year's 133.1 million euros. Like-for-like base revenues rose 19 percent, excluding fx effects.

Looking ahead, for the full year, the Group foresees adjusted Group EBITDA in the range of 105 million - 120 million euros, and revenues in the range of 700 million - 720 million euros.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT